Vascular Endothelial Growth Factor Receptor Inhibitors in Chinese Patients With Advanced Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Network Meta-Analysis and Cost-Effectiveness Analysis

Abstract

IntroductionTwo targeted drugs (apatinib and lenvatinib) show clinical efficacy in first-line treatment of Chinese patients with radioactive advanced iodine-refractory differentiated thyroid cancer (RAIR-DTC) and are recommended by the Chinese Society of Clinical Oncology guidelines. Considering the high clinical cost of long-term vascular endothelial growth factor receptor inhibitor administration and to determine which of the two targeted drugs is preferable, we opted to conduct a cost-effectiveness analysis (CEA) and network meta-analysis (NMA).Material and MethodsThe results of NMA and CEA included in the two phase III randomized clinical trials REALITY (NCT03048877) and Study-308 (NCT02966093), in which Bayesian NMA and CEA were performed on 243 and 149 Chinese patients, respectively, were retrieved. Overall survival and progression-free survival (PFS) for apatinib versus lenvatinib were determined by NMA. CEA involved the development of a 20-year Markov model to obtain the total cost and quality-adjusted life-years (QALYs), and this was followed by sensitivity and subgroup analyses.ResultsCompared with lenvatinib, apatinib therapy provided a 0.837 improvement in QALY and $6,975 reduction in costs. The hazard ratio of apatinib versus lenvatinib and the cost of the targeted drugs had a significant impact on the model. According to the sensitivity analysis, apatinib was more cost-effective and had no correlation with willingness-to-pay in China. Subgroup analysis showed that apatinib maintained PFS more economically.ConclusionNMA and CEA demonstrated that apatinib was more cost-effective compared to lenvatinib in the first-line treatment of Chinese RAIR-DTC patients.

Immune checkpoint inhibitors plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer: a cost-effectiveness analysis

“…Therefore, trial heterogeneity was minimized by calculating the corresponding HR, the methods used are all from previously published articles. 28,[44][45][46] Second, we inferred long-term clinical OS beyond the follow-up time from K-M curves from the CheckMate-649 (follow-up of 36.2 months) and KEYNOTE-859 (follow-up of 46.3 months) trials. This may be slightly different from the real data.…”

Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis

“…All other patients were provided with the best supportive care (BSC), with terminal care being provided to individuals that experienced treatment-related mortality. For this study, included Chinese patients were presumed to be 61 years of age, to weigh 65 kg, to have a total body surface area of 1.72 m 2 , a serum creatinine level of 1 mg/dL, and an area under the curve (AUC) of 5 mg/mL/min ( 11 , 13 , 14 ).…”

Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma: A network meta-analysis and cost-effectiveness analysis

“…The specific use of different drugs is detailed in Supplementary Table 4 . According to these RCTs and the published articles, we assumed that patients were 65 kg in weight, and 164 cm in height with a body surface area of 1.72 m 2 ( 25 , 26 ) ( Table 1 ).…”

“…The outputs we measured included the total cost, life-years (LYs), quality-adjusted LYs (QALYs), and incremental cost-effectiveness ratios (ICERs). The willingness-to-pay (WTP) was $37,653 per QALY in China ( 25 ).…”

“…As for sorafenib, we reconstructed the survival curves according to the survival data reported by each clinical trial. We got two parameters, shape (γ) and scale (λ), using R software ( 25 ). We used previously published utilities of 0.76 and 0.68 as the mean health utility value for the PFS and the PD state, respectively ( 27 ).…”